The complete chloroplast genome sequence of Ventilago leiocarpa Benth.
- Lu X et al (2021).
- Mitochondrial DNA B Resour.
- PubMed:
- 33763564
Researchers have developed a natural product-based drug to combat COVID-19 by targeting the key component involved in viral replication, the SARS-CoV-2 main protease (M). Phytochemicals from natural products were screened for drug likeness analysis and binding site-specific consensus-based molecular docking studies were carried out. The top compounds were tested for ADME-Tox properties and antiviral activity. Further molecular dynamics simulations and binding affinity estimation revealed that two analogues, demethoxyguiaflavine and strychnoflavine, have potential against M and can be validated through clinical studies. This study offers a potential solution for COVID-19 treatment through the use of natural products.
Researchers in Pakistan investigated the potential anti-Parkinson's activity of a methanolic extract of Cucurbita pepo (MECP) seeds. Using a rat model, they found that the extract improved motor functions. They also noted dose-dependent increases in catalase, superoxide dismutase, and glutathione levels, as well as decreases in malondialdehyde and nitrite levels. Molecular docking simulation suggested that certain phytoconstituents could bind to the active site of acetylcholine-esterase (AchE), a protein involved in the disease. Additionally, gene expression analysis revealed upregulation of alpha-synuclein and downregulation of TNF-alpha and IL-1beta. Finally, ADMET analysis predicted that selected phytochemicals exhibited moderately acceptable pharmacokinetics and toxicity. Overall, the results suggest that MECP could potentially ameliorate Parkinson's symptoms and may be a lead remedy for treatment.